Advertisement
Advertisement

OMER

OMER logo

Omeros Corporation

7.93
USD
+0.05
+0.64%
Dec 18, 14:01 UTC -5
Open

Omeros Corporation Profile

About

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.

Info & Links

CEO

Gregory A. Demopulos

Headquarters

201 ELLIOT AVENUE WEST
SEATTLE, WA 98119, UNITED STATES

Industry

Pharmaceuticals Major

Sector

Health Technology

Website

www.omeros.com

Auditor

Ernst & Young LLP

Share holders

84

Employees

198

Omeros Corporation Statistics

Valuation Measures

Market Capitalization2

459.54M

Enterprise Value

647.48M

Enterprise Value/EBITDA(ttm)

-3.75

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

--

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

--

Return on Invested Capital(ttm)

-254.40%

Return on Assets(ttm)

-49.92%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-172.76M

Net Income Available to Common(ttm)

-134.53M

Diluted EPS(ttm)

-2.31

Share Statistics

Beta (5Y Monthly)

1.97

52-Week Change

212.20%

S&P 500 52-Week Change

27.86%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

57.95M

Dividend Yield

0.00%

Float4

50.82M

% Held by Insiders

12.30%

% Held by Institutions

48.79%

Balance Sheet

Total Cash(mrq)

123.16M

Total Cash Per Share(mrq)

2.13

Total Debt(mrq)

189.46M

Total Debt/Equity(mrq)

-122.89%

Current Ratio(mrq)

2.96%

Quick Ratio(mrq)

2.96%

Book Value Per Share(mrq)

-2.66

Cash Flow

Operating Cash Flow Per Share(ytd)

-2.07

Free Cash Flow(ytd)

-119.96M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement